Literature DB >> 10163415

The expanding role of pharmacy and therapeutics committees. The 1990s and beyond.

W E Wade1, W J Spruill, A T Taylor, R L Longe, D W Hawkins.   

Abstract

Traditionally, pharmacy and therapeutics (P&T) committees have been responsible for overseeing the drug use process, using formulary systems to control drug costs. Primarily, these committees act in an advisory capacity as policy-recommending bodies within healthcare systems, for the specific purpose of promoting rational drug therapy. Methodologies utilised by these committees include drug use evaluation, medical staff education, continuous quality improvement, formulary restriction and therapeutic interchange. Future roles of P&T committees will include the evaluation of clinical outcomes information, including quality-of-life issues, to establish policies governing the use of drugs at all levels and in all types of healthcare.

Mesh:

Year:  1996        PMID: 10163415     DOI: 10.2165/00019053-199610020-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

1.  Conducting pharmacoeconomic evaluations in a hospital setting.

Authors:  L A Sanchez
Journal:  Hosp Pharm       Date:  1995-05

2.  Antibiotic therapeutic interchange program: six years of experience.

Authors:  L Frighetto; D Nickoloff; P Jewesson
Journal:  Hosp Formul       Date:  1995-02

3.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 4.  Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature.

Authors:  J T Lee; L A Sanchez
Journal:  Am J Hosp Pharm       Date:  1991-12

Review 5.  Quality of life instruments in the evaluation of new drugs.

Authors:  R Jaeschke; G H Guyatt; D Cook
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

6.  The formulary decision-making process in a health maintenance organisation setting.

Authors:  M D Shepherd; R D Salzman
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

7.  Containing cefoxitin costs through a program to curtail use in surgical prophylaxis.

Authors:  G Taylor; E Blondel-Hill; P Kibsey; E Friesen; R Tisdell; W Vaudry
Journal:  Can J Infect Dis       Date:  1993-09

8.  Fluconazole dosing in renal impairment: a drug usage evaluation.

Authors:  S B Moody; K J Sveska
Journal:  Hosp Formul       Date:  1993-05

9.  Antiulcer prescribing program in a state correctional system.

Authors:  M R Keith; D M Cason; D K Helling
Journal:  Ann Pharmacother       Date:  1994-06       Impact factor: 3.154

10.  Replacing lovastatin with pravastatin: effect on serum lipids and costs.

Authors:  L Korman; L Borysiuk
Journal:  Am J Health Syst Pharm       Date:  1995-05-15       Impact factor: 2.637

View more
  5 in total

Review 1.  Medication errors: hospital pharmacist perspective.

Authors:  Henk-Jan Guchelaar; Hadewig B B Colen; Mathijs D Kalmeijer; Patrick T W Hudson; Irene M Teepe-Twiss
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Prioritising drug and therapeutics committee (DTC) decisions: a national survey.

Authors:  Ee Lyn Tan; Richard O Day; Jo-anne E Brien
Journal:  Pharm World Sci       Date:  2006-12-23

3.  [Structure and activities of drug committees in Germany. Results of a survey of 143 hospitals. Pharmaco-economic Study Group and Rational Drug Therapy of the German Society of Clinical Pharmacology and Therapy].

Authors:  S Harder; P Thürmann; A Steioff
Journal:  Med Klin (Munich)       Date:  1998-02-15

Review 4.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

5.  Selection of medicines in Chilean public hospitals: an exploratory study.

Authors:  Juan F Collao; Felicity Smith; Nick Barber
Journal:  BMC Health Serv Res       Date:  2013-01-07       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.